Aurobindo Pharma Unit-VII Receives FDA VAI Classification

Aurobindo Pharma discloses US FDA's Voluntary Action Indicated (VAI) classification for its Unit-VII oral solid dosage facility.
The FDA inspection from January 28 to February 10, 2026, resulted in 9 observations on Form 483 initially.
The Establishment Inspection Report confirms the inspection is now closed with VAI status for the Jedcherla unit.